Jillion Therapeutics Inc.

Jillion Therapeutics Inc. is a Brooklyn-based for-profit biotechnology research company registered in the System for Award Management (SAM) through January 2026. The company specializes in advanced pharmaceutical research, focusing on developing innovative drug discovery platforms using cutting-edge technologies like DNA-encoded library (DEL) screening and artificial intelligence (AI) to identify novel therapeutic compounds for neurological and substance use disorders. Its research appears to be centered on leveraging sophisticated computational and molecular screening techniques to explore potential treatments for complex medical conditions.

The company has secured three federal grant awards from the National Institute on Drug Abuse (NIDA) and the National Institute on Aging (NIA), all of which are Phase I Small Business Innovation Research (SBIR) grants. These awards total approximately $896,257 and focus on developing therapeutic molecules for specific neurological challenges. The first two grants from NIDA involve identifying compounds to treat opioid use disorders by targeting specific G-protein coupled receptors (GPCRs), with one project exploring polypharmacological approaches to address substance use disorders by targeting multiple neurotransmitter systems, and another investigating the GPR26 receptor as a potential novel treatment pathway. The third grant from the NIA aims to develop compounds that can bind to and modify tau protein to potentially treat Alzheimer's disease and other neurodegenerative tauopathies. Each project utilizes the company's proprietary DNA-encoded library screening technology, demonstrating a consistent approach to drug discovery that combines advanced computational methods with molecular screening techniques.